Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

pediatrics

Roche Basel Switzerland

Roche’s Tecentriq combo scores FDA approval for melanoma

Drug approved for patients with BRAF protein mutations

- PMLiVE

NICE recommends Merck/Pfizer’s PD-L1 inhibitor Bavencio for kidney cancer

Picks up approval as a first-line treatment for advanced cancer

- PMLiVE

Roche pays $120m upfront for UCB’s anti-tau Alzheimer’s drug

Milestone payments could reach up to $2bn

- PMLiVE

Roche’s Actemra fails in late-stage severe COVID-19 study

Anti-inflammatory drug unable to improve clinical status of hospitalised patients

- PMLiVE

Pfizer, BioNTech identify and advance lead COVID-19 vaccine candidate

Companies pick the most promising candidate to take into phase 2/3

- PMLiVE

Biogen plans Spinraza study in SMA patients treated with Novartis’ Zolgensma

Company aims to extend market reach

Roche Basel Switzerland

Roche cites COVID-19 and biosimilars in Q2 decline

Pharmaceutical sales took a 4% hit in Swiss francs

- PMLiVE

US government pays $1.95bn for Pfizer/BioNTech’s COVID-19 vaccine

Initial order includes 100 million doses

- PMLiVE

Biogen raises full year guidance after beating Q2 expectations

Key drug franchises boost total revenues in the quarter

- PMLiVE

UK agrees further COVID-19 vaccine deals with Pfizer/BioNTech, Valneva

Government has already agreed similar deal with AstraZeneca

- PMLiVE

NICE recommends Astellas’ Xospata for NHS use

Cost-effectiveness watchdog backtracks on previous rejection

- PMLiVE

Roche pays $775m upfront to access Blueprint’s RET programme

Expands on initial deal that is worth up to $1bn

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links